Celgene stock plunged late Wednesday after Bristol-Myers Squibb 's (BMY) top shareholder said it opposes the $ 74 trillion of the two biopharma giants.
Wellington Management Company, which owns 8% of Bristol stock, agrees the drug giant should be seeking mergers and partnerships that broaden its future revenue base. However, the Celgene (CELG) did not achieve that, the investment management firm said.
"The transaction requires Bristol shareholders to accept too much risk and the terms Bristol shares to Celgene shareholders at "Wellington said in a written statement.
Further, any success will be" more difficult to achieve than depicted by company management. " The investment firm urged Bristol to seek alternative paths to create Bristol stock stock.
After-hours trading on today's stock market, Celgene stock tumbled 5.8%, near 85.50. Bristol stock, though, rose a fraction, near 51
Eli Lilly 's (LLY) $ 8 billion plan to acquire Loxo Oncology ( LOXO), and this week's announcement that Roche (RHHBY) will buy Spark Therapeutics (ONCE) for $ 4.8 trillion. GlaxoSmithKline (GSK) recently snapped up Tesaro for $ 5.1 trillion.
YOU MIGHT ALSO LIKE:
After Hours: These 5 Stocks Are Making Monster Earnings Moves
Biotech Stocks Pop After This Company Used CRISPR Drug In A Patient
This Cannabis Biotech Stock Popped Higher On Its CBD Oil Drug
Gene Therapy Space Heats Up As This Biotech Chases Down A Breakout